Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study to evaluate the safety and efficacy of the combination of Imfinzi (durvalumab) and sacituzumab govitecan as a frontline treatment of patients with triple-negative breast cancer (TNBC) and urothelial cancer (UC)

Next Previous
Trial Profile

A phase 1/2 study to evaluate the safety and efficacy of the combination of Imfinzi (durvalumab) and sacituzumab govitecan as a frontline treatment of patients with triple-negative breast cancer (TNBC) and urothelial cancer (UC)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Sacituzumab govitecan (Primary)
  • Indications Breast cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 30 Jul 2018 New trial record
  • 23 Jul 2018 According to an Immunomedics media release, Part one of the two-part Phase 1/2 studies will be co-funded by the two companies. Immunomedics will supply the study drug and AstraZeneca will utilize its existing clinical trial infrastructure to accelerate the enrollment of the sacituzumab govitecan and durvalumab combination.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top